


Efficient Designs: New Concepts in Clinical Trials

Inge Christoffer Olsen, PhD
OUH Clinical Trials Unit


FST Seminar 4 March 2025



Introduction

- What are efficient trial designs?
 - Comparison?
 - Parallel group design

Parallel group trials



Pros:

- Simple
- Few assumptions
- Easy implementation
- Easily interpreted
- Solid

Cons:

- Inefficient
- Rigid
- Often large
- Only answers one question

Example:

Bari-SolidAct


Mortality 10% vs 15%
1900 patients

Introduction

- What do we want to gain?
 - Shorter time
 - Fewer participants
 - Answer more clinical/scientific questions
 - Reuse infrastructure/data collection
- What are the drawbacks?
 - More complex
 - Challenging to contain false discovery rate
 - Operationally and clinically demanding

N-of-1 trials

- Carry-over effects
- Back to basic after wash-out
- Chronic, stable conditions
- Pros: efficient
- Cons: Strong assumptions



AB: quasi-experimental
ABA or ABAB: experimental

Grammatikopoulou, M.G., Gkouskou, K.K., Gkiouras, K. *et al.* The Niche of *n*-of-1 Trials in Precision Medicine for Weight Loss and Obesity Treatment: Back to the Future. *Curr Nutr Rep* 11, 133–145 (2022). <https://doi.org/10.1007/s13668-022-00404-5>

Example: Burst-trial (N-of-1 trial)

P: Chronic peripheral neuropathic pain

I: Spinal cord stimulation

C: No Spinal cord stimulation

O: Pain NRS 0-10 over last 7 days

Six treatment periods (I or C) of 2 weeks

Three cycles of two treatments (I or C)

12 weeks

10 patients

Factorial designs

- Two interventions and control

	Control	Food intervention
Control	Control	Food
Skin Intervention	Skin	Food + Skin

Pros:

- Assess two interventions in one trial
- Possible to assess the interaction
- Possibly efficient if the assumption of no interaction is valid

Cons:

- Difficult to interpret if there is an interaction

Example: PreventADALL

P: New born babies

I: Skin care (oil baths) and peanut, milk, wheat and egg introduction

C: No intervention

O: 1) Atopic dermatitis at 12 months
2) Food allergy at 36 months

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(19\)32983-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32983-6/fulltext)

Cluster-randomised trials

- Randomise clusters instead of individual patients
- E.g. hospitals, regions or departments

Example: LAPS trial

P: First time pregnant women

I: Follow Zhang's guideline

C: Follow WHO partogram

O: Caesarean sections

Pros:

- Pragmatic
- Quick enrolment
- Simple

Cons:


- Large sample size
- Many sites
- Generalisability?
- Causal interpretation?
- Best suited for strategies or non-drug interventions

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)31991-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31991-3/fulltext)

Stepped-wedge cluster-randomised trials

- Randomise the timing of intervention between clusters

Stepped-wedge cluster-randomised trials



Example: OPPORTUNI-C

P: Adults with Hepatitis C

I: Opportunistic treatment during hospitalisation

C: SoC Referral to outpatient clinic


O: Treatment completion

Platform trials

- A single trial infrastructure assessing multiple treatments for a single disease
- Master protocol
- Additional sub-protocols with new interventions
- Often common controls
- Basket and umbrella trials in cancer typical examples
- IMPRESS-NORWAY, EU-SolidAct, RECOVERY etc

Platform trials

Platform trial



[https://www.jclinepi.com/article/S0895-4356\(19\)30987-4/fulltext](https://www.jclinepi.com/article/S0895-4356(19)30987-4/fulltext)

Adaptive platform trials

- Adaptations can include
 - Interim analysis with early stopping (group sequential designs)
 - Adaptive randomisation
 - Take out or include new sub-populations
- Include both phase 2 and 3

EU-PROACT

Master protocol

Population: Hospitalised subjects with Viral Respiratory Tract Infection

- Overall design, used in Clinical trials agreements, used as text repository for the disease specific protocols

RS-PROACT

TRT A
TRT B
TRT A + B
TRT X
Control

Strong safety assessments, biobanking, focus on exploration

Continue treatment/interventions where activity is shown. Outcomes: viral dynamics, clinical, symptoms. Must show activity on at least one outcome. Bayesian analysis, could borrow information across diseases. No stopping for efficacy

TRT A
Control

Formal testing using group sequential frequentist methods for efficacy. Includes participants from phase 2. Outcome: clinical
No biobanking, focus on confirmation. No adjustment for multiplicity from phase 2

-Separate
application
to CTIS

FLU-PROACT

TRT A
TRT B
TRT A + B
TRT X
Control

TRT X
Control

-Separate
application
to CTIS

COV-PROACT

TRT A
TRT B
TRT A + B
TRT X
Control

-Separate
application
to CTIS

X-PROACT

TRT A
TRT B
TRT A + B
TRT X
Control

TRT X
Control

-Separate
application
to CTIS

Phase 2



Phase 3

Register-randomised trials

- Use already established registers to capture data
- Challenges in the informed consent and randomisation
- Example: TASTE trial
 - P: patients with ST-segment elevation myocardial infarction
 - I: routine intracoronary thrombus aspiration before primary percutaneous coronary intervention (PCI)
 - C: PCI alone
 - O: Death from any cause
- Very quick inclusion, fast answer

Pragmatic trials

- Lower the bars for achieving clear answers to the research question
- Focus on real world evidence
- Continuum between very unpragmatic to very pragmatic
- May introduce heterogeneity, larger sample sizes
- Cluster-randomised trials and register-randomised trials are examples of pragmatic trials
- Buzz-word to allow more leniency?

Non-randomised trials

- All included patients receive the experimental treatment
- Compare against historic controls
 - Actual data
 - Aggregated data (e.g. 95% mortality)
- Are the historical controls still relevant?
- What do you compare against
 - Mean outcome? Upper 95% confidence interval? Other?
- Remember the causal question!
 - Observational trial, use causal inference methods?